Overview

Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone

Status:
Completed

Trial end date:
2017-06-07

Target enrollment:

Participant gender:

Summary

In this study, the investigators investigate beneficial effects of ipragliflozin, newly developted SGLT2 inhibitor, on reduction in visceral fat area and degree of fatty liver in subjects with T2DM when added to metformin and pioglitazone therapy.

Phase:

Phase 4

Details

Lead Sponsor:

Yonsei University

Treatments:

Ipragliflozin
Metformin
Pioglitazone